The Canadian Cohort Obstructive Lung Disease (CanCOLD)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00920348|
Recruitment Status : Active, not recruiting
First Posted : June 15, 2009
Last Update Posted : August 27, 2018
Abstract Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death in Canada. COPD is not just a disease of men, nor is it solely a disease in old age. Women have been underrepresented and early disease has not been studied. Underdiagnosis of COPD remains a significant problem, and it may indicate an unmet healthcare need. This can potentially results not only in a patient been misinformed, but can lead to incorrect management.
Epidemiological research is needed to develop a framework to combat this major health problem, by better characterization of the population of men and women at risk and patients with early disease, by better understanding which factors modifiable through health interventions are related to health perception (health-related quality of life) and disease evolution.
This will be possible through a nationwide study, the Canadian Cohort Obstructive Lung disease (CanCOLD), a prospective longitudinal study. The CanCOLD study is built on the current ongoing prevalence nationwide study, the Canadian Obstructive Lung disease "COLD" study.
The CanCOLD will be the first study to assess prevalence of disease across Canada and its consequence in men and women, and to evaluate a conceptual model of disease severity based on patient's health perception (health-related quality of life). Ultimately, this project will extend to a longitudinal follow up (3 years or beyond) and will allow to have a better understanding of the lifestyle risk factors, not only smoking but also diet, physical activity, and co morbid conditions. This will be a great asset to shift from management of a single risk factor (tobacco control) to total COPD risk management. The results of the study will greatly help to assist decision makers in developing policies to improve the diagnosis, the management of COPD and to optimize health care services use.
|Condition or disease|
|COPD Chronic Obstructive Pulmonary Disease|
|Study Type :||Observational|
|Estimated Enrollment :||1500 participants|
|Official Title:||The Canadian Cohort Obstructive Lung Disease|
|Study Start Date :||January 2010|
|Estimated Primary Completion Date :||December 2022|
|Estimated Study Completion Date :||December 2022|
COPD moderate-severe(GOLD2-4)(post-BD FEV1/FVC<0.70 and FEV1<80% of pred.)
COPD mild (GOLD1)(post-BD FEV1/FVC<0.70 AND FEV1>=80% of pred.)
COPD at risk (ever smoker with post-BD FEV1/FVC>=0.70)
"Healthy control" never smokers without respiratory disease (post-BD FEV1/FVC>=0.70.
- What risk factors other than smoking determine the development and progression of COPD. [ Time Frame: One visit a year every 18 months ]
- What are the combinations of the disease and patient attributes that differentiate individuals (men/women) with COPD as they relate to relevant outcomes (symptoms, exacerbations, disease progression or death) [ Time Frame: One visit a year 18 months ]
- Is early detection of COPD with spirometry meaningful according to sex and ageing. [ Time Frame: One visit a year 18 months ]
Biospecimen Retention: Samples With DNA
- Biomarkers:IL-6, CRP, CC-16, SP-D"
- DNA for genetics, epigenetic and RNA for transcriptomics
- Markers for cardiovascular diseases: LDL, LDL and HDL sizes, Apo B, Apo A1, CRP, IL6, TNF alpha, Adiponectine, Leptine, Glucose and Insulin.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00920348
|Health Sciences Centre|
|Calgary, Alberta, Canada, T2N 4N1|
|Canada, British Columbia|
|Vancouver, British Columbia, Canada, V6Z 1Y6|
|Canada, Nova Scotia|
|Halifax, Nova Scotia, Canada, B3H 3A7|
|Kingston General Hospital|
|Kingston, Ontario, Canada, K7L 2V6|
|Ottawa Hospital General|
|Ottawa, Ontario, Canada, K1H 8L6|
|University of Toronto|
|Toronto, Ontario, Canada, M5T 2S8|
|Montreal Chest Institute|
|Montreal, Quebec, Canada, H2X 2P4|
|Royal University Hospital|
|Saskatoon, Saskatchewan, Canada, S7N 0W8|
|Institut universitaire de cardiologie et de pneumologie de Québec|
|Quebec, Canada, G1V 4G5|
|Principal Investigator:||Jean Bourbeau, M.D., M.Sc.||McGill University Health Centre/Research Institute of the McGill University Health Centre|
|Principal Investigator:||Wan Tan, M.D.||CAAA University of British Columbia|
|Principal Investigator:||François Maltais, M.D.||CFBA Université Laval|
|Principal Investigator:||Shawn Aaron, M.D., M.Sc.||OHGC Ottawa Hospital General Campus|
|Principal Investigator:||Denis O'Donnell, M.D.||CEDA Queen's University (Kinsgston)|
|Principal Investigator:||Darcy D Marciniuk, M.D.||CCAA University of Saskatchewan|
|Principal Investigator:||Robert Cowie, M.D.||CBBA University of Calgary|
|Principal Investigator:||Kenneth R. Chapman, M.D., M.Sc.||CEAA University of Toronto|
|Principal Investigator:||Paul Hernandez, M.D.||CHAA Dalhousie University (Nova Scotia)|
|Principal Investigator:||Mark J. FitzGerald, M.D.||CAAA University of British Columbia|
|Principal Investigator:||Donald Sin, M.D.||CAAA University of British Columbia|
|Principal Investigator:||Andrea Benedetti, Ph.D.||INUD McGill University Healty Center|
|Principal Investigator:||Yves Lacasse, M.D., M.Sc.||CPVR Institut universitaire de cardiologie et de pneumologie de Québec|
|Principal Investigator:||Pierre Ernst, M.D.||McGill University|
|Principal Investigator:||Harvey Coxson, M.D.||University of British Columbia|
|Principal Investigator:||Roger Goldstein, M.D.||CEAA University of Toronto|
|Principal Investigator:||Carlo Marra, Ph.D.||CAAA University of British Columbia|